The novel alpha-pharmaceutical radium-223 chloride may provide a new standard of care for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases.
MDV3100, a novel androgen receptor signaling inhibitor (ARSI), significantly improved overall survival (OS) in men with castration-resistant prostate cancer previously treated with docetaxel.
The use of preoperative magnetic resonance imaging (MRI) can help guide surgical decisions that may spare nerves in men with prostate cancer undergoing robotic-assisted laparoscopic prostatectomy (RALP).
In men undergoing active surveillance for low-risk prostate cancer, dutasteride delayed disease progression.
Dietary calcium intake is inversely associated with prostate-cancer risk, according to a study published online January 12 in the U.S. Centers for Disease Control and Prevention’s Preventing Chronic Disease.
There is no evidence of a mortality benefit for organized annual prostate-cancer screening versus usual care, according to a study published online January 6 in the Journal of the National Cancer Institute.
On-treatment related change in the bone scan index (BSI) is strongly associated with survival in patients receiving chemotherapy for metastatic prostate cancer.
This fact sheet provides information on symptoms, pain, causes, and treatments for testicular, testicle cancer.
